FDA calendar · August 2024 · built from SEC filings

PDUFA dates August 2024: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

2 PDUFA dates fell in August 2024: Symvess (August 10), LYMPHIR (August 13). The FDA calendar also recorded 52 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in August 2024

2 PDUFA target action dates in August 2024, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
August 10, 2024Humacyte, Inc.HUMASymvessSEC 8-K Exhibit 99.1, filed 2025-03-27
August 13, 2024CITIUS ONCOLOGY, INC.CTORLYMPHIRsec_424b, filed 2025-07-17

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

August 2024: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Aug 2024Month disclosed—ABEOComplete Response Letter—CRL issuedSEC 8-K Exhibit 99.1
August 1, 2024TECELRA (afamitresgene autoleucel)ADAPYFDA approvaladvanced synovial sarcoma andApprovedSEC 8-K Exhibit 99.1
Aug 2024Month disclosedfamitresgene autoleucelADAPYFDA approvalunresectable/metastatic synovial sarcomaApprovedSEC Form 10-K
Aug 2024Month disclosedTransConASNDFDA approvalhypoparathyroidism in adultsApprovedSEC Form 8-K
Aug 2024Month disclosedYORVIPATH (palopegteriparatide)ASNDFDA approvalhypoparathyroidism in adultsApprovedSEC Form 8-K
Aug 2024Month disclosed—BCDAFDA approval—ApprovedSEC 8-K Exhibit 99.1
Aug 2024Month discloseddenileukinCTORFDA approval—ApprovedSEC 8-K Exhibit 99.1
Aug 2024Month disclosedLYMPHIRCTORFDA approvalwith relapsed or refractory CTCLApprovedSEC 8-K Exhibit 99.1
Aug 2024Month disclosedCITI-002CTXRFDA approval—ApprovedSEC 8-K Exhibit 99.1
Aug 2024Month disclosed—EBSFDA approvalsmallpox disease in individuals determinedApprovedSEC 8-K Exhibit 99.1
Aug 2024Month disclosedCABOMETYX® (cabozantinib)EXELNDA/BLA accepted—CompletedSEC Form 10-K
August 1, 2024Jemperli (dostarlimab-gxly)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
Aug 2024Month disclosedLNZ100LENZNDA/BLA submission—CompletedSEC Form 10-Q
Aug 2024Month disclosedINDIGO (vorasidenib)NUVBFDA approvalIDH1- or IDH2-mutant grade 2 astrocytoma or oligodendrogliomaApprovedSEC 8-K Exhibit 99.1
Aug 2024Month disclosedOCU400OCGNFDA approval—ApprovedSEC Form 10-Q
Aug 2024Month disclosedLynozyfic (linvoseltamab)REGNComplete Response Letter—CRL issuedSEC Form 10-Q
Aug 2024Month disclosedNIKTIMVO (axatilimab)SNDXFDA approvalchronic graft-versus-host disease, or cGVHDApprovedSEC Form 10-K
Aug 2024Month disclosedRevuforj® (revumenib)SNDXFDA approvalchronic graft-versus-host disease, or cGVHDApprovedSEC Form 10-Q
Aug 2024Month disclosedTLX101TLXNDA/BLA submission—CompletedSEC 8-K Exhibit 99.1
Aug 2024Month disclosedZUSDURI (mitomycin)URGNNDA/BLA submission—CompletedSEC 8-K Exhibit 99.1
August 7, 2024CREXONTAMRXFDA approval—ApprovedSEC Form 10-Q
August 7, 2024IPX203AMRXFDA approval—ApprovedSEC Form 10-Q
August 7, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 7, 2024FABHALTA® (iptacopan)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
August 8, 2024Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)ARGXLabel expansion—ApprovedopenFDA Drugs@FDA
August 8, 2024Vyvgart (efgartigimod alfa)ARGXLabel expansion—ApprovedopenFDA Drugs@FDA
August 9, 2024—SPRYFDA approvalType 1 allergic reactionsApprovedSEC 8-K Exhibit 99.1
August 12, 2024Protonix Iv (pantoprazole sodium)PFELabel expansion—ApprovedopenFDA Drugs@FDA
August 14, 2024Livdelzi® (seladelpar)GILDFDA approvalTo treat primary biliary cholangitis (PBC)ApprovedFDA Novel Drug Approvals
August 14, 2024Niktimvo (axatilimab-csfr)INCYFDA approvalTo treat chronic graft-versus-host disease (cGVHD)ApprovedFDA Novel Drug Approvals
August 15, 2024Imfinzi® (durvalumab)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
August 15, 2024NexoBrid (anacaulase)MDWDLabel expansion—ApprovedopenFDA Drugs@FDA
August 15, 2024NexoBrid (anacaulase)VCELFDA approvaldeep partial-thickness and/or full-thickness thermal burnsApprovedSEC Form 10-K
August 19, 2024Rybrevant (amivantamab-vmjw)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
August 19, 2024Lazcluze (lazertinib mesylate)JNJFDA approvalTo treat non-small cell lung cancerApprovedFDA Novel Drug Approvals
August 19, 2024ARBLI (losartan)SCNXComplete Response Letter—CRL issuedFDA Complete Response Letters
August 20, 2024Amjevita (adalimumab-atto)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
August 20, 2024Lynozyfic (linvoseltamab-gcpt)REGNComplete Response Letter—CRL issuedFDA Complete Response Letters
August 22, 2024Beyfortus (nirsevimab-alip)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
August 23, 2024Pavblu (aflibercept-ayyh)AMGNFDA approval—ApprovedopenFDA Drugs@FDA
August 26, 2024PAVBLU® (aflibercept)REGNFDA approval—ApprovedSEC Form 10-Q
August 30, 2024Zeposia (ozanimod hydrochloride)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
August 30, 2024Prevymis (letermovir)MRKFDA approval—ApprovedopenFDA Drugs@FDA
August 30, 2024Prevymis (letermovir)MRKLabel expansion—ApprovedopenFDA Drugs@FDA

August 2024: dated readouts

DateDrugCompanyEventIndicationStatusSource
Aug 2024Month discloseddireclidine (NBI-1117568)NBIXTopline readoutschizophreniaPositiveSEC Form 10-K

August 2024: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Aug 2024Month disclosedneflamapimodCRVOTrial start—Completedsec_424b
Aug 2024Month disclosednimacimabSKYETrial start—CompletedSEC Form 10-K
Aug 2024Month disclosedluveltaSTROTrial startFRα-expressing non-small cell lung cancer, or NSCLC, with luveltaCompletedSEC Form 10-Q
Aug 2024Month disclosedmipletamigAPVOTrial start—CompletedSEC Form 10-K
Aug 2024Month disclosedATR-12AZTRTrial start—CompletedSEC 8-K Exhibit 99.1
Aug 2024Month disclosedTH103KLRSTrial start—CompletedSEC 8-K Exhibit 99.1
Aug 2024Month disclosedAMT-191QURETrial startFabry diseaseCompletedSEC Form 10-Q

3 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps August 2024. They are on each drug page and in the calendar API.

Questions

What PDUFA dates are in August 2024?

2 PDUFA dates fell in August 2024: Symvess (August 10), LYMPHIR (August 13). The FDA calendar also recorded 52 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.